Investment Ideas MagicMed aims to mainstream psychedelic therapy with world’s largest ‘Psybrary’ Through its university partnership, the firm wants to attract big pharma backers by making 100,000s of novel psychedelic derivatives for new precision medicine Jared GnamDecember 1, 2020
Psychedelics Psilocybin therapy 4 times more effective than antidepressants: study A first-of-its-kind clinical trial shows a dramatic drop in depression in over half of patients who received a synthetic version of the compound Jared GnamNovember 6, 2020
The weed wire UC Berkeley’s new psychedelic research centre wants to change your mind The new hub will focus on the rapidly advancing field by adding unique public education and spiritual components Jared GnamSeptember 16, 2020
The weed wire Mushroom company Mydecine acquires veteran-focused psychedelic firm With deep Canadian and U.S. military ties, NeuroPharm Inc. is about to launch psychedelic-based clinical trials Jared GnamJuly 15, 2020
The weed wire Champignon Brands grows research cap with AltMed acquisition The psychedelic medicine company has surged since going public last month and is quickly expanding its research footprint Jared GnamApril 13, 2020